Royalty Pharma RPRX
NASDAQ RPRX
$57.16 -0.47 (-0.82%)
At close: Oct 2, 2026 · 4:00 PM EDT

Royalty Pharma (RPRX) Asset Writedowns and Impairment (2026)

Updated

Royalty Pharma (RPRX) reported Asset Writedowns and Impairment of $69.4 million for Q1 2026.

Analysis

Royalty Pharma (RPRX) Asset Writedowns and Impairment (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Rocket Companies 43.94 Bn 29.62 Bn -
2 Orix 41.70 Bn 42.20 Bn -
3 Royalty Pharma 32.87 Bn 32.78 Bn -
4 Federal National Mortgage Association Fannie Mae 25.52 Bn 25.52 Bn -
5 Affirm Holdings 23.86 Bn 17.55 Bn -
6 Synchrony Financial 23.33 Bn -44.64 Bn -
7 Royal Gold 19.87 Bn 19.09 Bn 390.45 Mn
8 Annaly Capital Management 13.89 Bn 4.98 Bn -
9 Ares Capital 13.54 Bn 10.98 Bn -
10 Federal Home Loan Mortgage 13.00 Bn -5.74 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 69.40 Mn
API Access

Royalty Pharma Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=RPRX&period=max&api_key=YOUR_API_KEY